Skip to main
INSP

INSP Stock Forecast & Price Target

INSP Analyst Ratings

Based on 15 analyst ratings
Hold
Strong Buy 13%
Buy 20%
Hold 60%
Sell 0%
Strong Sell 7%

Bulls say

Inspire Medical Systems is poised for strong long-term growth due to its innovative and effective treatment for obstructive sleep apnea in a large and growing market. The company's positive first quarter results, with strong revenue and profitability despite headwinds from reimbursement changes and coding disruptions, demonstrate the resilience and potential of the business. However, near-term uncertainties and competition may limit growth in the short term, leading to a cautious "hold" recommendation from analysts.

Bears say

Inspire Medical Systems is facing significant challenges in the short term, with uncertainties surrounding reimbursement coding and potential competition from new neurostimulation devices in the obstructive sleep apnea market. These challenges have led to a significant decrease in the company's revenue guidance for 2026, and it may take several quarters for Inspire to turn the business around. While the company's technology and market position are still attractive, the ongoing reimbursement situation and potential impact from GLP-1 therapies on patient funnel growth are cause for concern. As a result, our outlook is negative and we have downgraded the stock to Neutral with a price target of $55, based on the assumption of 1x our FY27 revenue estimate.

INSP has been analyzed by 15 analysts, with a consensus rating of Hold. 13% of analysts recommend a Strong Buy, 20% recommend Buy, 60% suggest Holding, 0% advise Selling, and 7% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inspire Medical Systems Inc (INSP) Forecast

Analysts have given INSP a Hold based on their latest research and market trends.

According to 15 analysts, INSP has a Hold consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $72.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $72.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inspire Medical Systems Inc (INSP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.